Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2022 –2029 | |
|
|
USD 1.60 Billion |
| USD 2.96 Billion | |
| % | |
|
Global Vitreoretinal Disorders Market , By Type (Retinal Tear, Retinal Detachment, Diabetic Retinopathy, Macular Degeneration, Macular Hole, Others), Diagnosis (Digital fluorescein Angiography, Optical Coherence Tomography, Heidelberg Retinal Tomography, Indocyanine Green Angiography, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Ocular, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
The global vitreoretinal disorders market is expected to witness significant growth during the forecast period. Growing cases of diabetes and eye disorders drives the vitreoretinal disorders market. Due to environmental pollution, family history for ophthalmic diseases and adoption of unhealthy lifestyle also boost the growth of the vitreoretinal disorders market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global vitreoretinal disorders market in the forecast period 2022-2029. The expected CAGR of global vitreoretinal disorders market is tend to be around 8% in the mentioned forecast period. The market was valued at USD 1.6 billion in 2021, and it would grow upto USD 2.96 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Vitreoretinal disorders affect the major structure of the eye, including retina, macula and vitreous fluid. Retina is the light-sensitive layer present back side of the eye that helps focus images and transmit information to the optic nerves. Vitreous is the gel like fluid fill space between the lens and retina. The degeneration of the both retinal cells and vitreous fluid causes vitreoretinal disorders. Symptoms of vitreoretinal disorders includes painless unilateral floaters and/or visual loss, myopia, cataract and others.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Retinal Tear, Retinal Detachment, Diabetic Retinopathy, Macular Degeneration, Macular Hole, Others), Diagnosis (Digital fluorescein Angiography, Optical Coherence Tomography, Heidelberg Retinal Tomography, Indocyanine Green Angiography, Others), Treatment (Surgery, Medication, Others), Route of Administration (Oral, Parenteral, Ocular, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Aerie Pharmaceuticals, Inc. (U.S.), Allergan (Ireland), Bausch Health (U.S.), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Amorphex Therapeutics Holdings, Inc (U.S.), Alcon (Switzerland), Astellas Pharma Inc. (Japan), Bayer AG (Germany), Novartis AG (Switzerland), AstraZeneca (U.K.), Amgen Inc. (U.S.), Carl Zeiss Meditec AG (Germany), HumanOptics Holding AG (Germany), STAAR SURGICAL (U.S.)
|
|
Market Opportunities
|
|
Drivers
The global vitreoretinal disorders market is expected to witness a heavy growth rate in the forecast period driven by the factor of an aging population. The increasing demand in the global cataract market is a replication of growing elderly population, as people aged over 60 years frequently develop conditions in which eyes have reduced elasticity and in turn it affects the normal functioning. This boost the market growth.
Rising strategies such as new product launches could help the major market players gain a competitive edge over the other players. For instance, DORC received approval from Health Canada in January 2021 for the application of TissueBlue 0.025%. It would serve as an alternative for indocyanine green and other straining agents. This boosts the market growth
Opportunities
The growing adoption of initiatives, policies, and programs by the government authorities and many public organizations is improving the access to affordable vision care and this is anticipated to drive the market size. For instance, the International Agency for the Prevention of Blindness launched VISION 2020 with the aim to accelerate the prevention of blindness activities. The program included the World Sight Day which is an initiative that helps in the promotion of rising awareness associated with blindness and vision impairment.
Rise in the number of vitreoretinal disorders therapeutics being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global vitreoretinal disorders market over a forecast period.
The huge expenditure associated with the treatment of vitreoretinal disorders surely hamper the market growth.
This global vitreoretinal disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global vitreoretinal disorders market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The Covid-19 pandemic greatly affected the market due to reduction in number of patient visits in hospitals and clinics for vitreoretinal disorders and interruption of numerous alternative procedures and outpatient visits. Although, the market is expected to recover with continuation of activities across various domains and approval and administration of Covid-19 vaccines.
The global vitreoretinal disorders market is segmented on the basis of type, diagnosis, treatment, distribution channel, route of administration and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
Diagnosis
Treatment
Route of Administration
End User
Distribution Channel
The global vitreoretinal disorders market is analysed and market size insights and trends are provided by type, diagnosis, treatment, distribution channel, route of administration and end-user as referenced above.
The major countries covered in the global vitreoretinal disorders market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global vitreoretinal disorders market throughout the forecasted period due to increased government awareness programs, rising population of affluent patients and number of generic drugs.
North America dominates the market due to the improved medical reimbursement structure, high research and development and healthcare expenditure and skilled professionals.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The global vitreoretinal disorders market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global vitreoretinal disorders market.
Key players operating in the global vitreoretinal disorders market include:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.